185 related articles for article (PubMed ID: 32499298)
21. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
22. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
23. Hematogenous metastasis of ovarian cancer: rethinking mode of spread.
Pradeep S; Kim SW; Wu SY; Nishimura M; Chaluvally-Raghavan P; Miyake T; Pecot CV; Kim SJ; Choi HJ; Bischoff FZ; Mayer JA; Huang L; Nick AM; Hall CS; Rodriguez-Aguayo C; Zand B; Dalton HJ; Arumugam T; Lee HJ; Han HD; Cho MS; Rupaimoole R; Mangala LS; Sehgal V; Oh SC; Liu J; Lee JS; Coleman RL; Ram P; Lopez-Berestein G; Fidler IJ; Sood AK
Cancer Cell; 2014 Jul; 26(1):77-91. PubMed ID: 25026212
[TBL] [Abstract][Full Text] [Related]
24. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
25. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.
Capparelli C; Rosenbaum S; Berger AC; Aplin AE
J Biol Chem; 2015 Oct; 290(40):24267-77. PubMed ID: 26269601
[TBL] [Abstract][Full Text] [Related]
27. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
28. Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
Nakayama R; Zhang YX; Czaplinski JT; Anatone AJ; Sicinska ET; Fletcher JA; Demetri GD; Wagner AJ
Oncotarget; 2016 Mar; 7(13):16581-92. PubMed ID: 26918731
[TBL] [Abstract][Full Text] [Related]
29. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
30. miR-296-5p suppresses EMT of hepatocellular carcinoma via attenuating NRG1/ERBB2/ERBB3 signaling.
Shi DM; Li LX; Bian XY; Shi XJ; Lu LL; Zhou HX; Pan TJ; Zhou J; Fan J; Wu WZ
J Exp Clin Cancer Res; 2018 Nov; 37(1):294. PubMed ID: 30486894
[TBL] [Abstract][Full Text] [Related]
31. Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Camblin AJ; Tan G; Curley MD; Yannatos I; Iadevaia S; Rimkunas V; Mino-Kenudson M; Bloom T; Schoeberl B; Drummond DC; Lugovskoy AA; Louis CU; Askoxylakis V
Sci Rep; 2019 Nov; 9(1):16832. PubMed ID: 31728045
[TBL] [Abstract][Full Text] [Related]
32. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
[TBL] [Abstract][Full Text] [Related]
33. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
34. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
[TBL] [Abstract][Full Text] [Related]
35. NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.
Buac K; Xu M; Cronin J; Weeraratna AT; Hewitt SM; Pavan WJ
Pigment Cell Melanoma Res; 2009 Dec; 22(6):773-84. PubMed ID: 19659570
[TBL] [Abstract][Full Text] [Related]
36. XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
Ferreiro-Neira I; Torres NE; Liesenfeld LF; Chan CH; Penson T; Landesman Y; Senapedis W; Shacham S; Hong TS; Cusack JC
Clin Cancer Res; 2016 Apr; 22(7):1663-73. PubMed ID: 26603256
[TBL] [Abstract][Full Text] [Related]
37. Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Terai M; Kageyama K; Ozaki S; McCue PA; Sato T; Aplin AE
Cancer Res; 2015 Jul; 75(13):2737-48. PubMed ID: 25952648
[TBL] [Abstract][Full Text] [Related]
38. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.
Gravina GL; Mancini A; Sanita P; Vitale F; Marampon F; Ventura L; Landesman Y; McCauley D; Kauffman M; Shacham S; Festuccia C
BMC Cancer; 2015 Dec; 15():941. PubMed ID: 26620414
[TBL] [Abstract][Full Text] [Related]
39. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation.
Fock V; Plessl K; Draxler P; Otti GR; Fiala C; Knöfler M; Pollheimer J
J Cell Sci; 2015 Dec; 128(23):4306-16. PubMed ID: 26490994
[TBL] [Abstract][Full Text] [Related]
40. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha}v{beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling.
Ieguchi K; Fujita M; Ma Z; Davari P; Taniguchi Y; Sekiguchi K; Wang B; Takada YK; Takada Y
J Biol Chem; 2010 Oct; 285(41):31388-98. PubMed ID: 20682778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
